Cargando…

Autophagy Paradox: Strategizing Treatment Modality in Melanoma

The primordial autophagy process, originally identified as a starvation response in baker’s yeast, has since been shown to have a wide spectrum of functions other than survival. In many cases, it is accepted that autophagy operates as a key tumor suppressor mechanism that protects cells from adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Pangilinan, Christian, Xu, Xiaowei, Herlyn, Meenhard, Liang, Chengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883356/
https://www.ncbi.nlm.nih.gov/pubmed/36670319
http://dx.doi.org/10.1007/s11864-023-01053-8
_version_ 1784879491108044800
author Pangilinan, Christian
Xu, Xiaowei
Herlyn, Meenhard
Liang, Chengyu
author_facet Pangilinan, Christian
Xu, Xiaowei
Herlyn, Meenhard
Liang, Chengyu
author_sort Pangilinan, Christian
collection PubMed
description The primordial autophagy process, originally identified as a starvation response in baker’s yeast, has since been shown to have a wide spectrum of functions other than survival. In many cases, it is accepted that autophagy operates as a key tumor suppressor mechanism that protects cells from adverse environmental cues by enforcing homeostasis and maintaining the functional and structural integrity of organelles. Paradoxically, heightened states of autophagy are also seen in some cancers, leading to the prevailing view that the pro-survival aspect of autophagy might be hijacked by some tumors to promote their fitness and pathogenesis. Notably, recent studies have revealed a broad range of cell-autonomous autophagy in reshaping tumor microenvironment and maintaining lineage integrity and immune homeostasis, calling for a renewed understanding of autophagy beyond its classical roles in cell survival. Here, we evaluate the increasing body of literature that argues the “double-edged” consequences of autophagy manipulation in cancer therapy, with a particular focus on highly plastic and mutagenic melanoma. We also discuss the caveats that must be considered when evaluating whether autophagy blockade is the effector mechanism of some anti-cancer therapy particularly associated with lysosomotropic agents. If autophagy proteins are to be properly exploited as targets for anticancer drugs, their diverse and complex roles should also be considered.
format Online
Article
Text
id pubmed-9883356
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-98833562023-01-29 Autophagy Paradox: Strategizing Treatment Modality in Melanoma Pangilinan, Christian Xu, Xiaowei Herlyn, Meenhard Liang, Chengyu Curr Treat Options Oncol Skin Cancer (T Ito, Section Editor) The primordial autophagy process, originally identified as a starvation response in baker’s yeast, has since been shown to have a wide spectrum of functions other than survival. In many cases, it is accepted that autophagy operates as a key tumor suppressor mechanism that protects cells from adverse environmental cues by enforcing homeostasis and maintaining the functional and structural integrity of organelles. Paradoxically, heightened states of autophagy are also seen in some cancers, leading to the prevailing view that the pro-survival aspect of autophagy might be hijacked by some tumors to promote their fitness and pathogenesis. Notably, recent studies have revealed a broad range of cell-autonomous autophagy in reshaping tumor microenvironment and maintaining lineage integrity and immune homeostasis, calling for a renewed understanding of autophagy beyond its classical roles in cell survival. Here, we evaluate the increasing body of literature that argues the “double-edged” consequences of autophagy manipulation in cancer therapy, with a particular focus on highly plastic and mutagenic melanoma. We also discuss the caveats that must be considered when evaluating whether autophagy blockade is the effector mechanism of some anti-cancer therapy particularly associated with lysosomotropic agents. If autophagy proteins are to be properly exploited as targets for anticancer drugs, their diverse and complex roles should also be considered. Springer US 2023-01-21 2023 /pmc/articles/PMC9883356/ /pubmed/36670319 http://dx.doi.org/10.1007/s11864-023-01053-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Skin Cancer (T Ito, Section Editor)
Pangilinan, Christian
Xu, Xiaowei
Herlyn, Meenhard
Liang, Chengyu
Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title_full Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title_fullStr Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title_full_unstemmed Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title_short Autophagy Paradox: Strategizing Treatment Modality in Melanoma
title_sort autophagy paradox: strategizing treatment modality in melanoma
topic Skin Cancer (T Ito, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883356/
https://www.ncbi.nlm.nih.gov/pubmed/36670319
http://dx.doi.org/10.1007/s11864-023-01053-8
work_keys_str_mv AT pangilinanchristian autophagyparadoxstrategizingtreatmentmodalityinmelanoma
AT xuxiaowei autophagyparadoxstrategizingtreatmentmodalityinmelanoma
AT herlynmeenhard autophagyparadoxstrategizingtreatmentmodalityinmelanoma
AT liangchengyu autophagyparadoxstrategizingtreatmentmodalityinmelanoma